Bryan Goodwin
- Pharmacology top 0.01%
- Pharmacogenetics and Drug Metabolism 32
- Oncology top 0.2%
- Drug Transport and Resistance Mechanisms 33
-
- Hormonal Regulation and Hypertension 13
- Hepatology top 1%
- Biochemistry top 0.5%
-
- Cholesterol and Lipid Metabolism 13
-
- Estrogen and related hormone effects 13
-
- Liver Disease Diagnosis and Treatment 8
-
- Peroxisome Proliferator-Activated Receptors 6
- Epigenetics and DNA Methylation 6
- Co-authors
- Steven A. KliewerTimothy M. WillsonStacey A. JonesLinda B. MooreChristopher LiddleJon L. CollinsDavid D. McKeeGuizhen Luo
- Journals
- Molecular Pharmacology (6 papers)Journal of Biological Chemistry (6 papers)Molecular Endocrinology (4 papers)
- Partner nations
- United StatesAustraliaNetherlands
In The Last Decade
Bryan Goodwin
69 papers receiving 13.7k citations
Hit Papers
Peers
Comparison fields: 5 of 137
- Pharmacology 4.9k
- Oncology 6.5k
- Endocrinology, Diabetes and Metabolism 2.4k
- Hepatology 917
- Biochemistry 668
Countries citing papers authored by Bryan Goodwin
This map shows the geographic impact of Bryan Goodwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Goodwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Goodwin more than expected).
Fields of papers citing papers by Bryan Goodwin
This network shows the impact of papers produced by Bryan Goodwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Goodwin. The network helps show where Bryan Goodwin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bryan Goodwin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 87 | |
| 2 | 2021 | 28 | |
| 3 | 2019 | 48 | |
| 4 | 2015 | 240 | |
| 5 | 2012 | 76 | |
| 6 | 2008 | 117 | |
| 7 | 2005 | 164 | |
| 8 | 2004 | 87 | |
| 9 | 2003 | 161 | |
| 10 | 2003 | 41 | |
| 11 | 2003 | 55 | |
| 12 | 2002 | 112 | |
| 13 | Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptorbreakdown → | 2002 | 723 |
| 14 | 2002 | 212 | |
| 15 | 2002 | 106 | |
| 16 | A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesisbreakdown → | 2000 | 1598 |
| 17 | 1998 | 4 | |
| 18 | 1998 | 123 | |
| 19 | 1998 | 112 | |
| 20 | 1991 | 8 |
About Bryan Goodwin
Bryan Goodwin is a scholar working on Pharmacology, Biochemistry and Oncology, having authored 69 papers that have together received 14.1k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (33 papers), Pharmacogenetics and Drug Metabolism (32 papers), Cholesterol and Lipid Metabolism (13 papers), Hormonal Regulation and Hypertension (13 papers), Estrogen and related hormone effects (13 papers), Liver Disease Diagnosis and Treatment (8 papers), Peroxisome Proliferator-Activated Receptors (6 papers) and Epigenetics and DNA Methylation (6 papers). The work is most often cited by research in Pharmacology (4.9k citations), Oncology (6.5k citations) and Endocrinology, Diabetes and Metabolism (2.4k citations). Bryan Goodwin has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Steven A. Kliewer, Timothy M. Willson, Stacey A. Jones, Linda B. Moore, Christopher Liddle, Jon L. Collins, David D. McKee, Guizhen Luo, Jodi M. Maglich and Michael A. Watson. Their work appears in journals such as Molecular Pharmacology, Journal of Biological Chemistry, Molecular Endocrinology, Cell Metabolism and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.